U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H67N13O10
Molecular Weight 926.0732
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRV-120027

SMILES

[H][C@](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC)C(C)C)([C@@H](C)CC)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N[C@H](C)C(O)=O

InChI

InChIKey=XIEWFECSPPTVQN-KMIMAYJXSA-N
InChI=1S/C43H67N13O10/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48)/t24-,25+,29-,30-,31-,32-,34-,35-/m0/s1

HIDE SMILES / InChI

Molecular Formula C43H67N13O10
Molecular Weight 926.0732
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

TRV-120027 is a novel β-arrestin biased ligand of the angiotensin II type 1 receptor; it antagonizes canonical G-protein-mediated coupling while, in contrast to classical angiotensin II type 1 receptor antagonists, it engages β-arrestin-mediated signaling. Consequently, TRV-120027 inhibits angiotensin II-mediated vasoconstriction while, via β-arrestin coupling, it increases cardiomyocyte contractility. In preclinical studies, TRV-120027 not only produced vasodilation by antagonizing the AT1R-Gαq pathway but also enhanced cardiac performance by activating AT1R-β-arrestin signaling. Because of this unique pharmacological profile, TRV-120027 is now being evaluated in a phase II clinical trial as a novel therapeutic for acute heart failure (AHF).

Approval Year

PubMed

PubMed

TitleDatePubMed
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure.
2011 Nov

Sample Use Guides

Acute heart failure: 1, 5, or 25 mg/h of TRV-120027. Treatment was by IV infusion for 48-96 h.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:51:51 GMT 2023
Edited
by admin
on Sat Dec 16 01:51:51 GMT 2023
Record UNII
J1J4P3PQZD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRV-120027
Common Name English
D-ALANINE, N-METHYLGLYCYL-L-ARGINYL-L-VALYL-L-TYROSYL-L-ISOLEUCYL-L-HISTIDYL-L-PROLYL-
Common Name English
TRV027
Code English
TRV120027
Common Name English
TRV 027
Code English
SAR-VAL-TYR-ILE-HIS-PRO-D-ALA-OH
Common Name English
TRV 027 [WHO-DD]
Common Name English
TRV-027
Code English
Code System Code Type Description
DRUG BANK
DB12199
Created by admin on Sat Dec 16 01:51:51 GMT 2023 , Edited by admin on Sat Dec 16 01:51:51 GMT 2023
PRIMARY
CAS
1234510-46-3
Created by admin on Sat Dec 16 01:51:51 GMT 2023 , Edited by admin on Sat Dec 16 01:51:51 GMT 2023
PRIMARY
SMS_ID
300000022012
Created by admin on Sat Dec 16 01:51:51 GMT 2023 , Edited by admin on Sat Dec 16 01:51:51 GMT 2023
PRIMARY
FDA UNII
J1J4P3PQZD
Created by admin on Sat Dec 16 01:51:51 GMT 2023 , Edited by admin on Sat Dec 16 01:51:51 GMT 2023
PRIMARY
PUBCHEM
3082475
Created by admin on Sat Dec 16 01:51:51 GMT 2023 , Edited by admin on Sat Dec 16 01:51:51 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY